A randomised, open-label, multicentre, Phase III trial of in vivo purging with anti-CD38 (Daratumumab) to enhance myeloma autografting (IPANEMA)

Project: Research

Participants

Colleges, School and Institutes

Short titleA randomised, open-label, multicentre, Phase III trial of in vivo purging with anti-CD38 (Daratumumab) to enhance myeloma autografting (IPANEMA)
StatusActive
Effective start/end date1/10/2031/03/23